Can you compare the results, time lines, and insights gleaned from the LEADER trial with liraglutide, a GLP-1 RA, to those reported for EMPA-REG, which evaluated an SGLT2 inhibitor on CV risk?

Can you compare the results, time lines, and insights gleaned from the LEADER trial with liraglutide, a GLP-1 RA, to those reported for EMPA-REG, which evaluated an SGLT2 inhibitor on CV risk?

Can you compare the results, time lines, and insights gleaned from the LEADER trial with liraglutide, a GLP-1 RA, to those reported for EMPA-REG, which evaluated the effectiveness and safety of an SGLT2 inhibitor on CV risk?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Ralph DeFronzo, MD

Ralph DeFronzo, MD

Professor of Medicine
Chief of the Diabetes Division
The University of Texas Health Science Center at San Antonio
San Antonio, Texas